Bryan Quinn, MD
Nephrology · Carrollton, GANPI 1689887911
Payments from drug & device makers
Across 274 payments — averaging $18.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$767
- Amgen$702
- OPKO Pharmaceuticals, LLC$491
- Akebia Therapeutics Inc$464
- Otsuka America Pharmaceutical, Inc.$382
- Fresenius USA Marketing, Inc.$361
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,71793%
- Education$3827%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 40 | $767 |
| Amgen(2 entities) | 38 | $702 |
| OPKO Pharmaceuticals, LLC | 31 | $491 |
| Akebia Therapeutics Inc | 24 | $464 |
| Otsuka America Pharmaceutical, Inc. | 19 | $382 |
| Fresenius USA Marketing, Inc. | 19 | $361 |
| Aurinia Pharma U.S., Inc. | 10 | $252 |
| Bayer | 13 | $241 |
| Novartis | 9 | $195 |
| Travere Therapeutics, Inc. | 25 | $180 |
| Vifor Pharma, Inc. | 8 | $164 |
| Ardelyx, Inc. | 5 | $130 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Daiichi Sankyo Inc. | 5 | $101 |
| Mallinckrodt Hospital Products Inc. | 5 | $81 |
| GSK | 4 | $78 |
| Lilly USA, LLC | 3 | $54 |
| Apellis Pharmaceuticals, Inc. | 2 | $45 |
| Boehringer Ingelheim | 2 | $44 |
| Calliditas Therapeutics US Inc. | 2 | $42 |
| Sanofi | 1 | $40 |
| Vantive US Healthcare LLC | 1 | $31 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| One Lambda, Inc. | 1 | $22 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Cook Medical LLC | 1 | $18 |
| Nxstage Medical, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Novo Nordisk | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$125
How this compares
$5,099 in reported general payments places this provider in the 75th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuryxiaFerric Citrate | 47 | $125,880 |
| VelphoroSucroferric Oxyhydroxide | 33 | $109,849 |
| FarxigaDapagliflozin Propanediol | 88 | $74,813 |
| RayaldeeCalcifediol | 27 | $39,654 |
| JardianceEmpagliflozin | 34 | $32,648 |
| Lanthanum Carbonate | 24 | $28,145 |
| Sevelamer Carbonate | 131 | $21,534 |
| KerendiaFinerenone | 19 | $21,472 |
| Cinacalcet Hcl | 18 | $20,384 |
| VeltassaPatiromer Calcium Sorbitex | 15 | $16,610 |
| LokelmaSodium Zirconium Cyclosilicate | 12 | $8,435 |
| BrilintaTicagrelor | 15 | $7,428 |
| SpsSodium Polystyrene Sulfon/Sorb | 28 | $7,414 |
| Potassium Chloride | 97 | $1,746 |
| Hydralazine Hcl | 75 | $1,666 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Akebia Therapeutics IncAuryxia | $464 | $125,88047 claims |
| Fresenius USA Marketing, Inc.Velphoro | $361 | $109,84933 claims |
| AstraZenecaFarxiga, Lokelma, Brilinta | $767 | $90,676115 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $491 | $39,65427 claims |
| Boehringer IngelheimJardiance | $44 | $32,64834 claims |
| BayerKerendia | $241 | $21,47219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 388 nephrology providers in Georgia.
Other nephrology in Carrollton
- James TumlinLawrenceville$19.8M
- Chinedu NwekeAcworth$3.9M
- Vinayak RamanathLagrange$3.1M
- Harold HubertAugusta$2.8M
- Tamorie SmithColumbus$1.9M
- Barton BrezinaAugusta$1.5M
- Frederic Rahbari OskouiAtlanta$1.5M
- Rajeev ChauhanColumbus$1.1M
- Sagar PanseMacon$1.1M
- Laura MulloyAugusta$891K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.